Eric Bjerkholt serves as the Chief Financial Officer (CFO) at Mirum Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing therapies for rare liver diseases. In his role as CFO, Bjerkholt is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, and investor relations. His strategic financial leadership is crucial in guiding Mirum Pharmaceuticals through its growth phases and ensuring the company's fiscal health as it advances its mission to bring innovative treatments to patients. Prior to joining Mirum Pharmaceuticals, Bjerkholt held several high-level financial positions at notable companies within the life sciences industry. He previously served as CFO at Alder BioPharmaceuticals, where he played a pivotal role in guiding the company through its initial public offering (IPO) and subsequent acquisition by Lundbeck. Before that, he was CFO at Onyx Pharmaceuticals, where he helped navigate the company through its acquisition by Amgen. Bjerkholt's extensive experience in the biotech sector, particularly in managing the financial aspects of IPOs and mergers and acquisitions, has been instrumental in his success at Mirum Pharmaceuticals. Bjerkholt's career is marked by a series of significant achievements that highlight his expertise in financial strategy and corporate development. His ability to steer companies through complex financial transactions and growth strategies has earned him a respected reputation in the industry. At Mirum Pharmaceuticals, he continues to apply his skills to support the company's development and commercialization efforts, ensuring that financial resources are effectively allocated to advance the company's pipeline of therapies for rare liver diseases.